4,2'-Dihydroxy-3-methoxy-5'-methylchalcone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 4,2'-Dihydroxy-3-methoxy-5'-methylchalcone
• 英文别名: (E)-3-(4-hydroxy-3-methoxyphenyl)-1-(2-hydroxy-5-methylphenyl)prop-2-en-1-one
• 化学式: C₁₇H₁₆O₄
• 分子量: 284.31
• InChiKey: WNMAPNHXZFEFDI-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF
  申请人：The Regents of the University of California

  公开号：US20190008797A1

  公开（公告）日：2019-01-10

  Provided herein is a coligand for the estrogen receptor (ER) a subunit, and methods of use thereof in treating conditions associated with ER signaling in an individual. The present ERα coligand may be a cell type-selective, allosteric modulator of ERα signaling. The ERα coligand, when administered to an individual, may modulate ER agonist-dependent signaling in a tissue-selective manner.
• [EN] DRUGS FROM SUBSTITUTED PHENYL CINNAMYL KETONES<br/>[FR] MÉDICAMENTS OBTENUS À PARTIR DE PHÉNYL CINNAMYL CÉTONES SUBSTITUÉES
  申请人：NANYANG POLYTECHNIC

  公开号：WO2016153432A1

  公开（公告）日：2016-09-29

  The present invention relates to substituted phenyl cinnamyl ketones of Formula (I) for use in therapy: wherein R1 to R11 are defined as described in the specification, or a pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof, that are used in the treatment on RNA virus related infections. The present invention also relates to use of the compounds as described in the specification for the manufacture of a medicament in the treatment of a disease associated with RNA virus infections. The present invention also relates a method of preventing or treating a disease associated with a RNA virus related infection comprising administering to a subject in need of treatment a compound as described in the specification, or a pharmaceutically acceptable salt thereof.
• [EN] ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF<br/>[FR] CO-LIGANDS DES RÉCEPTEURS DES OESTROGÈNES ALPHA ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2017132135A1

  公开（公告）日：2017-08-03

  Provided herein is a coligand for the estrogen receptor (ER) α subunit, and methods of use thereof in treating conditions associated with ER signaling in an individual. The present ERα coligand may be a cell type-selective, allosteric modulator of ERα signaling. The ERα coligand, when administered to an individual, may modulate ER agonist-dependent signaling in a tissue-selective manner.